TABLE 1.
Clinical Indications and Their Frequencies
| Indication no. | Clinical indication | n |
| 18F-FDG PET/CT for diagnosis of tumor recurrence | 303 (18.3) | |
| 1 | Prior clinical suspicion of tumor recurrence | 56 (3.4) |
| 2 | Prior rising tumor markers or abnormal laboratory tests | 25 (1.5) |
| 3 | Prior suggestive imaging (CT or MRI) for tumor recurrence | 91 (5.5) |
| 4 | Prior indeterminate or suggestive 18F-FDG PET/CT scan for tumor recurrence | 131 (7.9) |
| 18F-FDG PET/CT before starting therapy for tumor recurrence | 64 (3.9) | |
| 5 | Restaging after confirmation of tumor recurrence | 18 (1.1) |
| 6 | If the extent of disease will alter therapy or if a new baseline was needed before change in therapy | 46 (2.8) |
| 18F-FDG PET/CT to assess therapy response for tumor recurrence | 507 (30.6) | |
| 7 | Therapy response assessment of recurrence | 266 (16) |
| 8 | Intratherapy assessment of recurrence | 210 (12.7) |
| 9 | Follow-up scan to assess the previous equivocal response | 31 (1.9) |
| Follow-up 18F-FDG PET/CT after completion of treatment for tumor recurrence | 785 (47.4) | |
| 10 | Follow-up for stable disease | 132 (8) |
| 11 | Follow-up for disease progression | 122 (7.4) |
| 12 | Follow-up of disease in remission or per clinical trial protocol | 531 (32) |
Data in parentheses are percentages.